HK1208470A1 - Biomarkers for use in integrin therapy applications - Google Patents
Biomarkers for use in integrin therapy applicationsInfo
- Publication number
- HK1208470A1 HK1208470A1 HK15107088.1A HK15107088A HK1208470A1 HK 1208470 A1 HK1208470 A1 HK 1208470A1 HK 15107088 A HK15107088 A HK 15107088A HK 1208470 A1 HK1208470 A1 HK 1208470A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- biomarkers
- therapy applications
- integrin therapy
- integrin
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261617451P | 2012-03-29 | 2012-03-29 | |
US201261648199P | 2012-05-17 | 2012-05-17 | |
PCT/US2013/032082 WO2013148316A1 (en) | 2012-03-29 | 2013-03-15 | Biomarkers for use in integrin therapy applications |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208470A1 true HK1208470A1 (en) | 2016-03-04 |
Family
ID=49261073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107088.1A HK1208470A1 (en) | 2012-03-29 | 2015-07-24 | Biomarkers for use in integrin therapy applications |
Country Status (5)
Country | Link |
---|---|
US (3) | US20150086570A1 (xx) |
EP (1) | EP2831104B1 (xx) |
ES (1) | ES2875535T3 (xx) |
HK (1) | HK1208470A1 (xx) |
WO (1) | WO2013148316A1 (xx) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
AU2013221585B2 (en) | 2012-02-17 | 2017-03-30 | Seagen Inc. | Antibodies to integrin alphavbeta6 and use of same to treat cancer |
AU2013284448B2 (en) | 2012-06-27 | 2019-04-18 | Berg Llc | Use of markers in the diagnosis and treatment of prostate cancer |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
PL228091B1 (pl) * | 2014-02-12 | 2018-02-28 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro |
MX2017002229A (es) | 2014-08-19 | 2017-05-09 | Merck Sharp & Dohme | Anticuerpos anti tigit. |
WO2016094425A1 (en) | 2014-12-08 | 2016-06-16 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
WO2017030823A2 (en) * | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
WO2017054058A1 (en) | 2015-09-30 | 2017-04-06 | Immunexpress Pty Ltd | Pathogen biomarkers and uses therefor |
US20180321242A1 (en) * | 2015-11-06 | 2018-11-08 | Immunexpress Pty Ltd | Viral biomarkers and uses therefor |
WO2017190218A1 (en) * | 2016-05-06 | 2017-11-09 | University Health Network | Liquid-biopsy signatures for prostate cancer |
AU2017327828B2 (en) * | 2016-09-16 | 2023-11-16 | Shanghai Henlius Biotech, Inc. | Anti-PD-1 antibodies |
CN106636330B (zh) * | 2016-09-21 | 2017-12-15 | 郁金泰 | 阿尔茨海默病的诊断和治疗药物 |
WO2021041317A1 (en) * | 2019-08-23 | 2021-03-04 | University Of Virginia Patent Foundation | Ddx17 and nlrc4 targeting for inflammatory diseases |
AU2020397070A1 (en) | 2019-12-05 | 2022-07-14 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1511738A4 (en) * | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
DE602004014795D1 (de) * | 2003-10-01 | 2008-08-14 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
US20070292887A1 (en) * | 2003-11-04 | 2007-12-20 | Bayer Pharmaceuticals Corporation | Immunohistochemical Methods |
WO2005069935A2 (en) * | 2004-01-20 | 2005-08-04 | University Of Medicine And Dentistry Of New Jersey | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF |
CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
EP2046374A4 (en) | 2006-07-10 | 2010-05-05 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS |
AU2007354317A1 (en) * | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
GB0803192D0 (en) * | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
EP2706358A3 (en) * | 2008-12-23 | 2014-05-07 | Merck Patent GmbH | Biomarkers for inhibitors with anti-angiogenic activity |
US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
-
2013
- 2013-03-15 EP EP13768248.0A patent/EP2831104B1/en active Active
- 2013-03-15 WO PCT/US2013/032082 patent/WO2013148316A1/en active Application Filing
- 2013-03-15 US US14/387,762 patent/US20150086570A1/en not_active Abandoned
- 2013-03-15 ES ES13768248T patent/ES2875535T3/es active Active
-
2015
- 2015-07-24 HK HK15107088.1A patent/HK1208470A1/xx unknown
-
2019
- 2019-11-14 US US16/683,644 patent/US20200248257A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/189,905 patent/US20220049301A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150086570A1 (en) | 2015-03-26 |
ES2875535T3 (es) | 2021-11-10 |
EP2831104B1 (en) | 2021-04-21 |
EP2831104A4 (en) | 2015-09-16 |
US20200248257A1 (en) | 2020-08-06 |
WO2013148316A1 (en) | 2013-10-03 |
EP2831104A1 (en) | 2015-02-04 |
US20220049301A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208470A1 (en) | Biomarkers for use in integrin therapy applications | |
HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
HK1203493A1 (en) | Substituted azabicycles and use thereof | |
EP2836608A4 (en) | TUBERCULOSIS BIOMARKERS AND USES THEREOF | |
EP2843024A4 (en) | BRIEF POLYGLYCOLIC ACID RESIN FIBERS FOR USE OF A DRILLING TREATMENT LIQUID | |
HK1210949A1 (en) | Combinations and uses thereof | |
EP2819749A4 (en) | BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF | |
HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
EP2872973A4 (en) | IMPROVEMENTS IN DEVICES FOR USE WITH COMPUTERS | |
HK1210809A1 (en) | Beta-hexosyl-transferases and uses thereof | |
SG11201405814WA (en) | Improvements in fluid conditioning | |
GB201211158D0 (en) | Biomarkers and uses thereof | |
HK1203232A1 (en) | Biomarker and use thereof | |
HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
GB201218438D0 (en) | Biomarkers and uses thereof | |
EP2922862A4 (en) | COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF | |
GB201202593D0 (en) | All in one | |
GB201217715D0 (en) | Improvements in swimfeeder devices | |
GB201210602D0 (en) | Improvement in compsite materials | |
GB201222541D0 (en) | Kiddibidet and pottibidet | |
GB201206393D0 (en) | Use | |
IL218974A0 (en) | Conaction bitwen coutch and playels | |
GB201202021D0 (en) | Co-sleeper and breastfeeder | |
GB201222457D0 (en) | Reversed mode | |
GB201114341D0 (en) | Reagent and use |